



<https://ppri.goeg.at/contact>

Euripid Stakeholder Dialogue Platform on Pricing of Medicinal Products took place on 21/9/2020

More than 60 **participants from different institutions and interest groups** (patient representatives, pharmacists, pharmaceutical industry, wholesalers, third party payers and **EURIPID** member state representatives) **attended** the 3rd Dialogue Platform organised **as online meeting** by the Euripid Secretariat affiliated to GÖG. The meeting focused on price transparency and the new EU Pharma Strategy.

Further information including agenda, background documents and presentations are available from our devoted European Health Policy Stakeholder Platform

<https://webgate.ec.europa.eu/hpf/network/home/79>

Please register via above link if you have not done so.


For requests and comments, please contact: euripid_intern@goeg.at.

WHO study on cross-country collaborations

Experts of the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (affiliated to the Pharmacoeconomics Department of the Austrian National Public Health Institute, GÖG) were principal investigators of the report "Cross-Country Collaborations to

improve access to medicines and vaccines in the WHO European Region” which was published by the WHO Regional Office for Europe.


The report assesses five government-led (cross-country) collaborations, which aim to improve access to essential medicines through joint activities: Baltic Procurement Initiative, Beneluxa Initiative, Fair and Affordable Pricing, Nordic Pharmaceutical Forum and Valletta Declaration. Their activities include information sharing, horizon scanning (to identify candidates for medicines in the pipeline), health technology assessments? (HTA), joint pricing / reimbursement negotiations and joint procurement of medicines. The report investigates challenges and facilitating factors and concludes with a checklist of prerequisites for successful cross-country collaborations.



Read more: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/WHO_CrossCountryCollaborations_Report_2020.pdf

German and Spanish corners added to the website

Since its re-launch in January 2019, the website of GÖG's Pharmacoeconomics Department has been serving as an information platform about pharmaceutical pricing and reimbursement policies in general and in particular with regard to the work of the Pharmacoeconomics Department. Since September 2020, the website also features a German and a Spanish corner, which provides users with key information related to pricing and reimbursement policies for medicines, key activities and projects of the Department such as PPRI, and publications.



We aim to contribute to affordable, equitable and sustainable access to safe, effective and quality essential medicines in Austria, Europe and globally.

Read more_German corner: <https://ppri.goeg.at/German>

Read more_Spanish corner: <https://ppri.goeg.at/Spanish>

CONFERENCES / TRAINING

Online capacity building

The WHO Collaborating Centre (WHO CC) for Pharmaceutical Pricing and Reimbursement Policies has long-term experience in training and consultancy activities targeted at pharmaceutical policy-makers.

The COVID-19 pandemic has prompted us to change the methodology in capacity-building and to provide training in a virtual format. Thus, despite the changed circumstances, the Centre continues to provide training at request – feel free to contact us!

Furthermore, as the 2020 WHO CC Summer School on Pharmaceutical Pricing and Reimbursement Policies, which had been scheduled to be held in Vienna in July 2020, was postponed, we are currently exploring options regarding the most appropriate date and format.

Follow-up information will be provided on our website: <https://ppri.goeg.at/>

INTERNATIONAL COOPERATION

PPRI comprises now more than 50 countries

The PPRI community is growing with Brazil (represented by the Brazilian Agency of Health Surveillance, Anvisa) and Saudi Arabia (represented by the Saudi Food & Drug Authority) having recently joined the PPRI network. Thus, as of September 2020, the PPRI network comprises around 90 institutions from 51 countries (including all 27 EU Member States) and European and international organisations. The focus of the PPRI network still lies within the European region, but since some of the challenges in pharmaceutical policy are of global nature, the PPRI Secretariat believes that the information exchange with other regions in the world is beneficial for everyone.

Read more: https://ppri.goeg.at/PPRI_network

Master thesis on shortages of COVID-19 related medicines

Dr Diana Ivonne Rodríguez Sánchez had a research placement at the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies in spring 2020. In July 2020, she graduated from the Master Erasmus Mundus Joint Master's Degree Programme in European Public Health. In her master's thesis, she analysed publicly accessible shortage registers in Austria, Italy and Spain with the aim to identify shortages of COVID-19 related medicines.

European perspective in 10-year anniversary report of the German AMNOG system

In 2010, Germany introduced the AMNOG legislation to assess the therapeutic benefit of new medicines and to regulate their prices. In the light of this anniversary, the 2020 "AMNOG report" of the German health insurance "DAK-Gesundheit", studied the progress in affordable and sustainable access to medicines during the last decade. Dr Sabine Vogler of the Austrian National Public Health Institute analysed the German system from a European perspective in one of the guest contributions. She also participated in an online event on 10 September 2020, in which the report was presented and its findings were discussed.

Contribution: Vogler S: Gratulation mit Wunschliste – Europäischer Blick aus dem Nachbarland [Congratulations and a wish list – European view from the neighbouring country]. In: Greiner W, Witte J, Gensorowsky D, Pauge S: AMNOG-Report 2020. 10 Jahre AMNOG – Rückblick und Ausblick [AMNOG report 2020. 10 years of AMNOG – Looking back and outlook], medhochzwei 2020, ed. by Storm A (in German)

Read more: <https://www.dak.de/dak/download/report-2335144.pdf>

FURTHER PUBLICATIONS

Technical reports and book chapters

Vogler S, Zimmermann N, Dedet G, Lam J, Pedersen HB: Pharmaceutical Pricing and Reimbursement Systems in Eastern Europe and Central Asia. WHO Regional Office for Europe, 2020, Copenhagen (in English and in Russian)

Vogler S: Medicines Pricing: Limitations of Existing Policies and New Models. In: Babar ZUB (ed.): Global Pharmaceutical Policy. Springer. June 2020, pp. 99-137

Articles

Gamba S, Pertile P, Vogler S.: The impact of managed entry agreements on pharmaceutical prices. Health Economics 2020. <https://doi.org/10.1002/hec.4112>

Rintoul A, Colbert A, Garner S, Kotwani A, Vogler S, Bouvy J et al.: Medicines with one seller and many buyers: strategies to increase the power of the payer. BMJ 2020; 369 :m1705

List of publications: <https://ppri.goeg.at/publications>